Payment overview · 2025
General Payments
$4,123.25
254 reported records · 18 companies
Healthcare provider profile · identity verified
John Christopher Strunk
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · DOTHAN, AL · NPI 1811983596
Verified facts
What the public records show
CMS Open Payments records show John Christopher Strunk received $4,123.25 in general payments during 2025 across 254 reported records.
Vanda Pharmaceuticals Inc. accounted for 16.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Aristada, Austedo Xr, Auvelity, Azstarys, Caplyta, Fanapt, Ingrezza, Loreev Xr, Lybalvi, Nurtec Odt, Rexulti, Sunosi, Trintellix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 209 claims for Vraylar by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARISTADA as an associated drug or biological on 76041 records involving 17486 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Aristada by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYBALVI as an associated drug or biological on 93784 records involving 20135 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Lybalvi by this doctor in 2024.
Almatica Pharma LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOREEV XR as an associated drug or biological on 9621 records involving 4446 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Loreev Xr by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Auvelity by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Sunosi as an associated drug or biological on 19758 records involving 6305 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Sunosi by this doctor in 2024.
Corium, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Azstarys as an associated drug or biological on 54930 records involving 15827 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Azstarys by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Caplyta by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Abilify Maintena by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 251 claims for Rexulti by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Ingrezza by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 251 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Nurtec Odt by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trintellix by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Austedo by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Austedo Xr by this doctor in 2024.
Vanda Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FANAPT as an associated drug or biological on 95605 records involving 21383 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Fanapt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $692.54 | 16.8% | 30 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $591.96 | 14.4% | 31 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $494.26 | 12.0% | 39 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $489.44 | 11.9% | 26 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $365.38 | 8.9% | 19 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $286.13 | 6.9% | 17 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $264.42 | 6.4% | 24 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $239.06 | 5.8% | 24 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $209.56 | 5.1% | 17 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $199.11 | 4.8% | 11 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $92.64 | 2.2% | 5 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $74.44 | 1.8% | 4 | 2025 |
| Neos Therapeutics, LP | Unresolved — no canonical attribution shown | $36.88 | 0.9% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $24.10 | 0.6% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.49 | 0.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.66 | 0.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.56 | 0.4% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $13.62 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,119.46 | 253 |
| Education | $3.79 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $692.54 | 30 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $607.62 | 32 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $494.26 | 39 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $489.44 | 26 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $286.13 | 17 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $283.65 | 13 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $266.88 | 15 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $264.42 | 24 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $224.29 | 23 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $209.56 | 17 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $199.11 | 11 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $92.64 | 5 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $81.73 | 6 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $74.44 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $24.10 | 1 | 2025 |
Source payment records
|
|||||
| EXXUA Normalized: exxua |
Drug | Neos Therapeutics, LP | $20.92 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $18.49 | 1 | 2025 |
Source payment records
|
|||||
| Adzenys XR-ODT Normalized: adzenys xr odt |
Drug | Neos Therapeutics, LP | $15.96 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.56 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.56 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.77 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $13.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ARISTADA aristada |
2025 | Aristada | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Auvelity auvelity |
2025 | Auvelity | 2024 | 50 | exact normalized | Medicare Part D |
| Azstarys azstarys |
2025 | Azstarys | 2024 | 86 | exact normalized | Medicare Part D |
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FANAPT fanapt |
2025 | Fanapt | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LOREEV XR loreev xr |
2025 | Loreev Xr | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LYBALVI lybalvi |
2025 | Lybalvi | 2024 | 61 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 251 | exact normalized | Medicare Part D |
| Sunosi sunosi |
2025 | Sunosi | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 209 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
209 | 29 |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | ARISTADA open payments reported associated product |
CMS Open Payments — General Payments 76041 supporting records · 17486 recipient NPIs · example record 1222428566 |
Aristada · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | LYBALVI open payments reported associated product |
CMS Open Payments — General Payments 93784 supporting records · 20135 recipient NPIs · example record 1222428566 |
Lybalvi · 2024 Exact normalized brand match · 1 Part D row |
61 | 14 |
| Almatica Pharma LLC Exact reporting entity; no affiliate inference |
2025 | LOREEV XR open payments reported associated product |
CMS Open Payments — General Payments 9621 supporting records · 4446 recipient NPIs · example record 1209929018 |
Loreev Xr · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Auvelity open payments reported associated product |
CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064 |
Auvelity · 2024 Exact normalized brand match · 1 Part D row |
50 | 12 |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Sunosi open payments reported associated product |
CMS Open Payments — General Payments 19758 supporting records · 6305 recipient NPIs · example record 1235293059 |
Sunosi · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Corium, LLC Exact reporting entity; no affiliate inference |
2025 | Azstarys open payments reported associated product |
CMS Open Payments — General Payments 54930 supporting records · 15827 recipient NPIs · example record 1185762907 |
Azstarys · 2024 Exact normalized brand match · 1 Part D row |
86 | 11 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
251 | 41 |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
251 | 41 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
144 | 15 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Vanda Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | FANAPT open payments reported associated product |
CMS Open Payments — General Payments 95605 supporting records · 21383 recipient NPIs · example record 1232940535 |
Fanapt · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 1832 | 210 |
| Clonazepam | Clonazepam | 1447 | 204 |
| Mirtazapine | Mirtazapine | 1104 | 235 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 1101 | 169 |
| Trazodone Hcl | Trazodone Hcl | 799 | 150 |
| Quetiapine Fumarate | Quetiapine Fumarate | 751 | 146 |
| Lorazepam | Lorazepam | 740 | 112 |
| Doxepin Hcl | Doxepin Hcl | 695 | 148 |
| Buspirone Hcl | Buspirone Hcl | 665 | 121 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 609 | 119 |
| Aripiprazole | Aripiprazole | 549 | 110 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 513 | 85 |
| Duloxetine Hcl | Duloxetine Hcl | 491 | 76 |
| Bupropion Xl | Bupropion Hcl | 464 | 76 |
| Oxcarbazepine | Oxcarbazepine | 429 | 117 |
| Risperidone | Risperidone | 428 | 94 |
| Fluoxetine Hcl | Fluoxetine Hcl | 419 | 82 |
| Sertraline Hcl | Sertraline Hcl | 379 | 68 |
| Olanzapine | Olanzapine | 359 | 80 |
| Lamotrigine | Lamotrigine | 330 | 49 |
| Zolpidem Tartrate | Zolpidem Tartrate | 281 | 35 |
| Diazepam | Diazepam | 278 | 42 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 274 | 38 |
| Citalopram Hbr | Citalopram Hydrobromide | 261 | 41 |
| Methylphenidate Hcl | Methylphenidate Hcl | 254 | 39 |
| Rexulti | Brexpiprazole | 251 | 41 |
| Modafinil | Modafinil | 249 | 45 |
| Topiramate | Topiramate | 245 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 226 | 39 |
| Atomoxetine Hcl | Atomoxetine Hcl | 224 | 45 |
| Amitriptyline Hcl | Amitriptyline Hcl | 210 | 45 |
| Vraylar | Cariprazine Hcl | 209 | 29 |
| Belsomra | Suvorexant | 204 | 37 |
| Gabapentin | Gabapentin | 203 | 33 |
| Paroxetine Hcl | Paroxetine Hcl | 195 | 39 |
| Nortriptyline Hcl | Nortriptyline Hcl | 185 | 28 |
| Benztropine Mesylate | Benztropine Mesylate | 181 | 50 |
| Vyvanse | Lisdexamfetamine Dimesylate | 177 | 34 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 173 | 20 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 160 | 26 |
| Prazosin Hcl | Prazosin Hcl | 158 | 32 |
| Austedo | Deutetrabenazine | 144 | 15 |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 144 | 38 |
| Memantine Hcl | Memantine Hcl | 139 | 38 |
| Imipramine Hcl | Imipramine Hcl | 131 | 22 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 127 | 12 |
| Divalproex Sodium | Divalproex Sodium | 120 | 24 |
| Ziprasidone Hcl | Ziprasidone Hcl | 116 | 15 |
| Paliperidone Er | Paliperidone | 105 | 29 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 100 | 15 |
| Lurasidone Hcl | Lurasidone Hcl | 96 | 19 |
| Alprazolam Er | Alprazolam | 95 | 23 |
| Propranolol Hcl | Propranolol Hcl | 91 | 15 |
| Temazepam | Temazepam | 91 | 17 |
| Azstarys | Serdexmethylphen/Dexmethylphen | 86 | 11 |
| Haloperidol | Haloperidol | 85 | 27 |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 83 | 13 |
| Divalproex Sodium Er | Divalproex Sodium | 65 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 65 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 61 | 12 |
| Lybalvi | Olanzapine/Samidorphan Malate | 61 | 14 |
| Abilify Maintena | Aripiprazole | 59 | suppressed |
| Eszopiclone | Eszopiclone | 56 | 16 |
| Donepezil Hcl | Donepezil Hcl | 55 | 18 |
| Venlafaxine Hcl | Venlafaxine Hcl | 52 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 51 | suppressed |
| Armodafinil | Armodafinil | 50 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 50 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 50 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 47 | 18 |
| Primidone | Primidone | 46 | suppressed |
| Omeprazole | Omeprazole | 45 | 15 |
| Quviviq | Daridorexant Hcl | 45 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 45 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 44 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 44 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 44 | 16 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 41 | suppressed |
| Lisinopril | Lisinopril | 39 | 14 |
| Ondansetron Odt | Ondansetron | 38 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 35 | 15 |
| Haloperidol Decanoate | Haloperidol Decanoate | 35 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 35 | suppressed |
| Loreev Xr | Lorazepam | 35 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 34 | suppressed |
| Alprazolam Xr | Alprazolam | 33 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 33 | 14 |
| Caplyta | Lumateperone Tosylate | 31 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 26 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Metformin Hcl | Metformin Hcl | 24 | 11 |
| Ingrezza | Valbenazine Tosylate | 21 | suppressed |
| Austedo Xr | Deutetrabenazine | 20 | suppressed |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 19 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 19 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 18 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Sunosi | Solriamfetol Hcl | 18 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 17 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Aristada | Aripiprazole Lauroxil | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Fanapt | Iloperidone | 13 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 13 | 11 |
| Losartan Potassium | Losartan Potassium | 13 | 11 |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Meloxicam | Meloxicam | 13 | suppressed |
| Potassium Chloride | Potassium Chloride | 13 | suppressed |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 12 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 12 | suppressed |
| Fluvoxamine Maleate Er | Fluvoxamine Maleate | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 12 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 12 | suppressed |
| Perphenazine-Amitriptyline | Perphenazine/Amitriptyline Hcl | 12 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 12 | suppressed |
| Seroquel Xr | Quetiapine Fumarate | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Zaleplon | Zaleplon | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,123.25 · 254 records | Vanda Pharmaceuticals Inc. | ARISTADA, AUSTEDO XR, Adzenys XR-ODT, Auvelity, Azstarys, CAPLYTA, COBENFY, Dyanavel XR, EXXUA, FANAPT, INGREZZA, Jornay PM, LOREEV XR, LYBALVI, NURTEC ODT, QULIPTA, REXULTI, Sunosi, TRINTELLIX, VRAYLAR, WAKIX, ZAVZPRET | 20 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Aristada play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error